Ther Clin Risk Manag. 2006 Sep;2(3):325-8. doi: 10.2147/tcrm.2006.2.3.325.
Recently a number of new therapies have been introduced to treat psoriasis, but concerns have been expressed about their high cost. The purpose of this study was to determine whether most psoriasis treatments lie within the accepted range of cost-utility.
32 patients with moderate to severe psoriasis were administered the Euro-Qol 5 Dimension (EQ-5D) survey to calculate their health state utility. Economic modeling was performed with a range of therapeutic costs applying the calculated utility score. Paired t-tests were used to calculate significance.
At the conclusion of 2 weeks of therapy, the mean psoriasis area and severity index (PASI) improved 35% to 7.2 (p<0.001). The mean health state utility score on the EQ-5D improved 11.5% from 77.7 units before therapy to 86.7 units after therapy (p=0.007).
A therapy that achieves at least a PASI 35 would be considered cost-effective by conventional standards if it does not exceed $33 600 in cost.
最近有许多新的疗法被引入治疗银屑病，但人们对其高成本表示担忧。本研究的目的是确定大多数银屑病治疗方法是否在可接受的成本效益范围内。
32 名中重度银屑病患者接受了 Euro-Qol 5 维度（EQ-5D）调查，以计算他们的健康状态效用。对一系列治疗费用进行了经济建模，应用计算出的效用评分。采用配对 t 检验计算显著性。
治疗 2 周后，银屑病面积和严重程度指数（PASI）平均改善 35%，至 7.2（p<0.001）。EQ-5D 的平均健康状态效用评分从治疗前的 77.7 单位提高到治疗后的 86.7 单位，提高了 11.5%（p=0.007）。
如果一种疗法的成本不超过 33600 美元，那么其达到 PASI 35 的疗效就可以被认为符合传统标准的成本效益。
